An Introduction to Viral Infections
Viruses are intracellular parasites, and are the most widespread organisms on Earth. They cause acute disease, such as gastroenteritis or influenza, or chronic disease, such as HIV or hepatitis. Emerging infections, such as SARS, MERS, avian influenza, Ebola and most recently, the devastating SARS-Cov-2 pandemic pose an increasing threat to human health. Numerous substances with antiviral activity are in clinical use. The use of protease inhibitors and highly active antiretroviral therapy has transformed the management of HIV. Promising emerging therapeutic approaches include neutralising antibodies. In addition, the current success of mRNA vaccines against SARS-Cov-2 heralds a new era of vaccinology. However, the threat of drug- and vaccine-resistant viral mutants are a major problem.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Our supporting partners do not constitute an endorsement of the content on this page.
Viral Infections Content
Joshua Parsons Cohen, EACS 2021: Persistence on Guideline-recommended HIV Treatment
touchINFECTIOUSDISEASES met with Dr Joshua Parsons Cohen (Independent Healthcare Analyst, Healthcare Analytics, Boston, MA, USA) to discuss the persistence on guideline-recommended HIV treatment, and which treatment regimens were associated with the highest persistence. The abstract entitled: ‘Persistence on guideline-recommended HIV treatment: Comparison among US Medicaid beneficiaries newly initiating treatment with single-versus multiple-tablet regimens’ was presented […]
Philipp Schommers, EACS 2021: The use of bNAbs as a Curative Strategy in HIV
It was fantastic to meet with Dr Philipp Schommers (University Hospital Cologne, University of Cologne, Cologne, Germany) to discuss the clinical development of broadly neutralizing antibodies in HIV and their potential as a curative strategy. The presentation entitled: ‘The antibody component: bnAbs in HIV cure’ was presented at the 18th European AIDS Conference (EACS 2021), […]
Esmita Charani: Tackling Global Antimicrobial Resistance
We caught up with touchINFECTIOUS DISEASES expert faculty member, Dr Esmita Charani (Imperial College London, London, UK), to discuss her recent research into the future research priorities to optimise antimicrobial use in humans, and what research gaps still remain. Useful resources: Research roadmap for optimising the use of antibiotics in humans Publication available here: Charani […]
18th European AIDS Conference 2021: Welcome from Sanjay Bhagani
Dr Sanjay Bhagani invites you to join the 18th European AIDS Conference (EACS 2021). The conference will be organised in a hybrid format from October 27-30, 2021. The onsite Conference in London will take place, following a comprehensive COVID-19 health and safety concept, complemented by an engaging and interactive online platform that mirrors the scientific […]
Christoph Spinner, IAS 2021: Results from the DISCOVER Open Label Study
We had the pleasure to meet with Christoph Spinner (University Hospital rechts der Isar, Technical University of Munich (TUM), Munich, Germany) to discuss the DISCOVER open label phase results. The abstract entitled: ‘Outcomes of participants switching from F/TDF to F/TAF for PrEP: week 48 results from the DISCOVER open label phase’ was presented at IAS […]
Tomas Jelinek: Unmet Needs, Prevention and Treatment of Chikungunya
It was a great pleasure to meet with Tomas Jelinek (The Berlin Center for Travel and Tropical Medicine, Berlin, Germany) to discuss chikungunya virus, its health burden and the unmet needs in its prevention and treatment. Question: Could you tell us a little about chikungunya, its health burden and the unmet needs in its prevention […]
Lulu Nair, IAS 2021: The Health Burden of HIV among Young Women in Africa
touchINFECTIOUSDISEASES were pleased to meet with Lulu (Gonasagrie) Nair (Stellenbosch University, Stellenbosch, South Africa) to discuss the the health burden of HIV among young women and adolescent girls in Africa, and the need for pre-exposure prophylaxis. The abstract entitled: ‘Adherence to the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in […]
Lulu Nair, IAS 2021: Interim Results from the REACH study
touchINFECTIOUSDISEASES were pleased to meet with Lulu (Gonasagrie) Nair (Stellenbosch University, Stellenbosch, South Africa) to discuss the interim results from the REACH study. The abstract entitled: ‘Adherence to the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in Africa: interim results from the REACH study’ was presented at IAS 2021 – […]
Heiner Wedemeyer, EASL ILC 2021: Bulevirtide Phase 3 Hepatitis D Study
It was a pleasure to be able to speak to Prof. Heiner Wedemeyer (Hannover Medical School, Hannover, Germany) about the interim results from the phase 3 MYR301 study investigating bulevirtide monotherapy in patients with chronic hepatitis D. His abstract entitled ‘Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!